How many email patterns does Biovica International AB use?

Biovica International AB uses 4 known email patterns.

What domain does Biovica International AB use for work emails?

Biovica International AB uses biovica.com for work email addresses.

Most Common Email Formats at Biovica International AB

Biovica International AB's most common email format is First.Last@biovica.com (ex. John.Doe@biovica.com), used for 94% of biovica.com addresses. Biovica International AB uses 4 email patterns.

@biovica.com

4 patterns

Format	Example	Share of biovica.com
First.Last@biovica.comMost common	John.Doe@biovica.com	94%
First.Middle.Last@biovica.com	John.Michael.Doe@biovica.com	3%
FLast@biovica.com	JDoe@biovica.com	1%
First@biovica.com	John@biovica.com	2%

Frequently Asked Questions

What does Biovica International AB do?

Biovica International AB was founded in 2009 and operates in the Medical Equipment Manufacturing industry, alongside similar companies like Genomic Vision, HTG Molecular Diagnostics and OncoDNA. You can visit biovica.com or contact Biovica International AB's headquarters by phone at

+46-18-444-4****

. Explore Biovica International AB's company overview page for more information.

What is Biovica International AB's email address format?

Biovica International AB's email format typically follows the pattern of First.Last@biovica.com; this email format is used 94% of the time. Other contacts within LeadIQ's database had email formats such as First.Middle.Last@biovica.com and FLast@biovica.com. Looking for more contact data? Unlock accurate emails and phone numbers from millions of profiles verified in real-time.

How many employees does Biovica International AB have currently?

Biovica International AB has approximately 32 employees as of October 2026. Key team members to contact include Ceo: A. R., Chief Financial Officer: M. E. and Vice President Qa/Ra: S. L. For more team information and contact data, explore Biovica International AB's employee directory with LeadIQ.

Biovica International AB Email Format

Medical Equipment ManufacturingUppsala, Sweden11-50 Employees

Biovica International AB develops and commercializes blood-based biomarker assays intended to monitor responses to modern cancer therapies and help predict patient outcomes. Its DiviTum TKa assay measures cell proliferation and has demonstrated potential for early assessment of treatment effectiveness in various clinical trials. The company collaborates with leading cancer institutes and pharmaceutical developers bringing next-generation therapies to market, and maintains a CLIA-certified laboratory in the United States that provides the DiviTum TKa test as a service. In Europe, DiviTum TKa is CE-labeled and MPA-registered, and Biovica maintains ISO 13485 certification for its quality management systems. The company is based in Uppsala, Sweden, and operates as a relatively small to mid-sized player in the medical equipment manufacturing sector. A notable recent development is Biovica's 2025 collaboration with Outcomes4Me to support personalized navigation for cancer patients.

Most Common Email Formats at Biovica International AB

@biovica.com

Need a specific person's email?

Frequently Asked Questions

What does Biovica International AB do?

What is Biovica International AB's email address format?

How many employees does Biovica International AB have currently?

Biovica International AB Email Format

Ready to create more pipeline?

Everything for prospecting,
in one platform.

What you can expect from LeadIQ:

Ready to create more pipeline?

Most Common Email Formats at Biovica International AB

@biovica.com

Need a specific person's email?

Frequently Asked Questions

What does Biovica International AB do?

What is Biovica International AB's email address format?

How many employees does Biovica International AB have currently?

Biovica International AB Email Format

Ready to create more pipeline?

Everything for prospecting,in one platform.

What you can expect from LeadIQ:

Ready to create more pipeline?

Everything for prospecting,
in one platform.